Impact of statin use on outcomes in triple negative breast cancer

Simona F. Shaitelman, Michael C. Stauder, Pamela Allen, Sangeetha Reddy, Susan Lakoski, Bradley Atkinson, Jay Reddy, Diana Amaya, William Guerra, Naoto Ueno, Abigail Caudle, Welela Tereffe, Wendy A. Woodward

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Purpose: We sought to investigate if the use of HMG Co-A reductase inhibitors (statins) has an impact on outcomes among patients with triple negative breast cancer (TNBC). Methods: We reviewed the cases of women with invasive, non-metastatic TNBC, diagnosed 1997-2012. Clinical outcomes were compared based on statin use (defined as ever use during treatment vs. never use). We identified a subset of women for whom a 5-value lipid panel (5VLP) was available, including total cholesterol, low density lipoprotein, high density lipoprotein, very low density lipoprotein, and triglycerides. The Kaplan-Meier method was used to estimate median overall survival (OS), distant metastases-free survival (DMFS), and local-regional recurrence-free survival (LRRFS). A Cox proportional hazards regression model was used to test the statistical significance of prognostic factors. Results: 869 women were identified who met inclusion criteria, with a median follow-up time of 75.1 months (range 2.4-228.9 months). 293 (33.7%) patients used statins and 368 (42.3%) had a 5VLP. OS, DMFS, and LRRFS were not significant based on statin use or type. Controlling for the 5VLP values, on multivariable analysis, statin use was significantly associated with OS (HR 0.10, 95% CI 0.01-0.76), but not with DMFS (HR 0.14, 95% CI 0.01-1.40) nor LRRFS (HR 0.10 95% CI 0.00-3.51). Conclusions: Statin use among patients with TNBC is not associated with improved OS, although it may have a benefit for a subset of patients. Prospective assessment would be valuable to better assess the potential complex correlation between clinical outcome, lipid levels, and statin use.

Original languageEnglish (US)
Pages (from-to)2026-2032
Number of pages7
JournalJournal of Cancer
Volume8
Issue number11
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

    Fingerprint

Keywords

  • Breast cancer
  • Cholesterol
  • Statin
  • Triple negative

ASJC Scopus subject areas

  • Oncology

Cite this

Shaitelman, S. F., Stauder, M. C., Allen, P., Reddy, S., Lakoski, S., Atkinson, B., Reddy, J., Amaya, D., Guerra, W., Ueno, N., Caudle, A., Tereffe, W., & Woodward, W. A. (2017). Impact of statin use on outcomes in triple negative breast cancer. Journal of Cancer, 8(11), 2026-2032. https://doi.org/10.7150/jca.18743